Skip to main content
Premium Trial:

Request an Annual Quote

Cenix, Janssen Expand siRNA Delivery Collaboration


Cenix BioScience said this week that it has signed a collaboration and technology license agreement with Belgium-based Janssen Research and Development to co-develop Cenix's DARE siRNA delivery technology to improve the in vivo applicability of experiments that use the gene-silencing molecules.

According to Cenix, the deal represents an expansion of an ongoing partnership with Janssen focused on improving in vivo siRNA-based target validation methodologies in the central nervous system.

Cenix noted that certain of the technologies developed through the arrangement are expected to be useful for therapeutic siRNA delivery, as well, and will be fully owned by Cenix.

Specific terms of the arrangement were not disclosed.